Novel Therapeutic Approaches Targeting Post-Translational Modifications in Lung Cancer

Lung cancer is one of the most common cancers worldwide. It consists of two different subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Despite novel therapeutic options such as immunotherapy, only 20% of lung cancer patients survive the disease after five years. This l...

Descripción completa

Detalles Bibliográficos
Autores principales: Baietti, Maria Francesca, Sewduth, Raj Nayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865455/
https://www.ncbi.nlm.nih.gov/pubmed/36678835
http://dx.doi.org/10.3390/pharmaceutics15010206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865455/
https://www.ncbi.nlm.nih.gov/pubmed/36678835
http://dx.doi.org/10.3390/pharmaceutics15010206

Ejemplares similares